ISRCTN46399359已完成不适用
The European CUP trial: a randomised trial in adults with poor risk relapsed follicular non-hodgkin's lymphoma
Baxter AG (Switzerland)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Relapsed follicular non-Hodgkin's lymphoma, after a first or subsequent remission, requiring therapy because of at least one of the following:
- •1.1. B symptoms
- •1.2. Rapidly progressive disease
- •1.3. Bone marrow failure
- •1.4. Life threatening organ failure
- •2. Aged 15 - 65 years
- •3. No central nervous system (CNS) involvement
- •4. No previous radiotherapy greater than 2000 cGy to the mediastinum or abdomen, precluding total body irradiation
- •5. No previous myeloablative therapy
- •6. No prior malignancies, except non-melanomatous skin cancer or cervical carcinoma stage I
- •7. Adequate cardiac, neurologic, liver and renal function
- •8. No evidence of histlogically proven transformation
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中(未招募)
不适用
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTPersistent asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-006512-30-DKAstraZeneca AB8,250
进行中(未招募)
1 期
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTPersistent asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-006512-30-GRAstraZeneca AB8,250
进行中(未招募)
1 期
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTEUCTR2006-006512-30-GBAstraZeneca AB8,250
进行中(未招募)
不适用
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTEUCTR2006-006512-30-ISAstraZeneca AB8,250
进行中(未招募)
1 期
A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5 micrograms of 1 or 2 inhalations twice daily in the treatment of persistent asthma. EUROSMART - EUROSMARTPersistent asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-006512-30-FRAstraZeneca AB8,250
